Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Intrahepatic cholangiocarcinoma (iCCA) can originate from the large bile duct group (segment bile ducts and area bile ducts), small bile duct group (septal bile ducts and interlobular bile ducts), and terminal bile duct group (bile ductules and canals of Hering) of the intrahepatic biliary tree, which can be histopathological corresponding to large duct type iCCA, small duct type iCCA and iCCA with ductal plate malformation pattern, and cholangiolocarcinoma, respectively. The challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies, tissue structures, growth patterns, invasive behaviors, immunophenotypes, molecular mutations, and surgical prognoses. For these reasons, this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA, mainly based on the 5 edition of the World Health Organization Classification of Tumours of the Digestive System.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752808PMC
http://dx.doi.org/10.14218/JCTH.2023.00118DOI Listing

Publication Analysis

Top Keywords

bile ducts
16
bile duct
12
duct group
12
expert consensus
8
pathological diagnosis
8
intrahepatic cholangiocarcinoma
8
bile
8
duct type
8
type icca
8
subtypes icca
8

Similar Publications

Objective: To demonstrate the effectiveness and safety of intraluminal endoscopic treatment of patients with adenomas of the major duodenal papilla and familial adenomatous polyposis.

Material And Methods: Over the past 4 years, 13 patients with adenomas of the major duodenal papilla and familial adenomatous polyposis underwent surgery in our hospital. Of these, 7 patients had exclusively extrapapillary adenomas without signs of spread to the ducts.

View Article and Find Full Text PDF

Cholesterol homeostasis dysregulation is a primary risk factor for atherosclerosis (AS) development. Fisetin, a flavonoid compound, has shown promise in regulating cholesterol homeostasis by enhancing transintestinal cholesterol excretion (TICE). This study aimed to investigate the regulatory effects and underlying mechanisms of fisetin in AS.

View Article and Find Full Text PDF

[Protection of sphincter of Oddi function from the viewpoint of confluence diseases of pancreaticobtlary ducts].

Zhonghua Yi Xue Za Zhi

September 2025

Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.

The confluence diseases of pancreaticobiliary ducts are important causes of benign and malignant diseases such as inflammation, stones, and tumors of the biliary and pancreatic systems. Endoscopic retrograde cholangiopancreatography (ERCP) has played an important role in the diagnosis and treatment of the confluence diseases of pancreaticobiliary ducts and the biliary and pancreatic systems diseases. However, excessive damage to the sphincter of Oddi (SO) can break the biliary tightness, leading to complications such as reflux cholangitis, stones, and tumors.

View Article and Find Full Text PDF

A Data-Driven Mathematical Model for Clonorchiasis with Seasonality.

Bull Math Biol

September 2025

School of Mathematical and Statistical Sciences, University of Texas Rio Grande Valley, Edinburg, Texas, 78539, USA.

Clonorchiasis is a foodborne disease caused by parasites and transmitted to humans through intermediate hosts. Clonorchis sinensis parasitizes in the bile ducts of human liver and causes organ lesions. The cercariae and metacercaria of Clonorchis sinensis have seasonal variations and may be affected by high water temperature in summer.

View Article and Find Full Text PDF

Background: Textbook outcome (TO), an emerging composite metric for surgical quality assessment, has recently gained recognition for evaluating perioperative results. Laparoscopic transcystic common bile duct exploration (LTCBDE) has become a widely adopted minimally invasive technique for treating cholecystolithiasis with choledocholithiasis. Despite its growing clinical application, TO has not yet been formally defined for LTCBDE, nor have its failure-associated risk factors been systematically examined.

View Article and Find Full Text PDF